Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression.
Xufeng LuDazhuan E XinJuanjuan K DuQuanli C ZouQian WuYanan S ZhangWenhai DengJicheng YueXing S FanYuanyuan ZengXiaju ChengXue S LiZhaoyuan HouMan MohanTing C ZhaoXiaomei LuZhijie ChangLi-Yan XuYu SunXiongbing ZuYu ZhangY Eugene ChinnPublished in: Cancer research (2022)
LOXL2 loss reprograms the epigenetic landscape to promote uterine cancer initiation and progression and repress the efficacy of anti-PD-1 immunotherapy, indicating that LOXL2 is a tumor suppressor.